Author: Ravi Shankar

BEIJING, Sept. 29, 2026 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced the appointment of Mr. Philip Yifei Bao to its board of directors (the “Board”), effective September 29, 2026. Following Mr. Bao’s appointment, the Board consists of ten directors, including three independent directors.

“We are pleased to welcome Mr. Bao to our Board,” said Mr. Hui Li, Chairman of the Board of Luckin Coffee. “His extensive experience investing in consumer businesses, deep knowledge of the China market and broad global perspective will bring valuable insights to the Board. We look forward to working closely with him as Luckin Coffee continues to execute its long-term growth strategy and create sustainable value for its shareholders.”

Mr. Bao is the Director of Private Equity China within the Private Equity platform of Mubadala Investment Company P.J.S.C. (“Mubadala”), where he leads Mubadala’s private equity investments in China. He is based in Beijing. Prior to joining Mubadala, Mr. Bao worked in private equity and investment banking in London from 2011 to 2017. Mr. Bao holds Bachelor of Arts and Master of Engineering (Hons) degrees in Electrical and Electronic Engineering from Gonville and Caius College, University of Cambridge.

SAFE HARBOR STATEMENTS

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. Luckin Coffee may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Luckin Coffee’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the expense, timing and outcome of existing or future legal and governmental proceedings or investigations in connection with Luckin Coffee; the outcome and effect of the restructuring of Luckin Coffee’s financial obligations; Luckin Coffee’s growth strategies; its future business development, results of operations and financial condition; the effect of the non-reliance identified in, and the resultant restatement of, certain of Luckin Coffee’s previously issued financial results; the effectiveness of its internal control; its ability to retain and attract its customers; its ability to maintain and enhance the recognition and reputation of its brand; its ability to maintain and improve quality control policies and measures; its ability to establish and maintain relationships with its suppliers and business partners; trends and competition in the coffee industry or the food and beverage sector in general; changes in its revenues and certain cost or expense items; the expected growth of China’s coffee industry or China’s food and beverage sector in general; governmental policies and regulations relating to Luckin Coffee’s industry; and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in Luckin Coffee’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Luckin Coffee undertakes no obligation to update any forward-looking statement, except as required under applicable law.

ABOUT LUCKIN COFFEE INC.

Luckin Coffee Inc. (OTC: LKNCY) has pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. Empowered by proprietary technologies, Luckin Coffee pursues its vision to build a world-class coffee brand and become a part of everyone’s daily life. Luckin Coffee was founded in 2017 and is based in China. For more information, please visit investor.lkcoffee.com.

INVESTOR AND MEDIA CONTACTS

Investor Relations Contact
Luckin Coffee IR
Email: ir@lkcoffee.com

Bill Zima
ICR
Phone: 646 880 9039

Media Relations Contact
Luckin Coffee PR
Email: pr@lkcoffee.com

LIMASSOL, Cyprus, Sept. 29, 2026 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”), today announced the preliminary results of the previously announced tender offer by the Company to purchase for cash up to $20,000,000 in value of its ordinary shares, no par value per ordinary share (each, a “share”), or up to 1,813,236 shares, at a purchase price of $11.03 per share, net to the seller in cash, without interest, less any applicable withholding taxes, which expired at 5:00 p.m., Eastern Time, on September 28, 2026 (the “Expiration Time”).

Based on the preliminary count by Continental Stock Transfer & Trust Company, the depositary for the tender offer (the “Depositary”), 56,830 shares were properly tendered and not properly withdrawn prior to the Expiration Time, including 280 shares tendered through notice of guaranteed delivery, which may be delivered within the two business days settlement period.

In accordance with the terms and conditions of the tender offer, and based on the preliminary results reported by the Depositary, the Company expects to purchase up to 56,830 shares through the tender offer at a price of $11.03 per share, for an aggregate cost of approximately $626.8 thousand, excluding fees relating to the tender offer. The number of shares that the Company expects to purchase in the tender offer represents approximately 0.3% of the total number of issued ordinary shares of the Company outstanding as of the commencement of the tender offer on August 31, 2026.

The Company expects to have approximately 18.1 million shares outstanding immediately following payment for the shares purchased in the tender offer. The shares acquired pursuant to the tender offer will be held by the Company as treasury shares, and will remain available for the Company to issue in the future.

The number of shares expected to be purchased by the Company is preliminary and subject to change. The preliminary information contained in this press release is subject to confirmation by the Depositary and is based on the assumption that all shares tendered through notice of guaranteed delivery will be delivered within the two business days settlement period. The final number of shares to be purchased by the Company will be announced following the completion by the Depositary of the confirmation process. Payment for the shares accepted for purchase under the tender offer will occur promptly thereafter.

D.F. King & Co., Inc. is serving as the information agent for the tender offer, and Continental Stock Transfer & Trust Company is serving as the Depositary. For all questions regarding the tender offer, please contact the information agent, D.F. King & Co., Inc., by calling +1 (800) 549-6864, or by emailing gdev@dfking.com.

About GDEV

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Pixel Gun 3D and others have accumulated over 550 million installs and $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc.

Certain information regarding the tender offer

The information in this press release describing GDEV Inc.’s tender offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares of GDEV Inc. in the tender offer. The tender offer will only be made pursuant to the Offer to Purchase, the related Letter of Transmittal and other related materials filed as part of the Tender Offer Statement on Schedule TO, in each case as may be amended or supplemented from time to time. Shareholders should read such Offer to Purchase and related materials carefully and in their entirety because they contain important information, including the various terms and conditions of the tender offer.

Shareholders of GDEV Inc. may obtain a free copy of the Tender Offer Statement on Schedule TO, the Offer to Purchase and other documents that GDEV Inc. is filing with the Securities and Exchange Commission from the Securities and Exchange Commission’s website at www.sec.gov. Shareholders may also obtain a copy of these documents, without charge, from D.F. King & Co., Inc., the information agent for the tender offer, by calling (800) 549-6864 (U.S. toll‑free), or by emailing gdev@dfking.com. Shareholders are urged to carefully read all of these materials prior to making any decision with respect to the tender offer. Shareholders and investors who have questions or need assistance may call D.F. King & Co., Inc., the information agent for the tender offer, toll free at (800) 549-6864, or may email D.F. King & Co., Inc. at gdev@dfking.com.

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2025 Annual Report on Form 20-F, filed by the Company on March 31, 2026, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –

– To-date, all patients achieving MRD-negativity reached CR within one year of treatment –

– Across all forty-five patients, NXC-201 produced an 89% (40/45) CR rate as assessed by independent review committee –

– In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98% (44/45) –

– No relapses observed for any patient who reached CR or MRD-negativity to-date –

– No neurotoxicity or enterocolitis has been observed to-date –

– NEXICART-2 final readout and BLA submission planned mid-2027 –

– Virtual investor event today Sep 29 at 8:00am ET: https://events.q4inc.com/attendee/484851283/ –

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced positive results of an 89% (40/45) complete response (CR) rate in an interim update across all forty-five NEXICART-2 patients, advancing NXC-201 as a potential best-in-class therapy for AL Amyloidosis. All twenty-five new relapsed/refractory AL Amyloidosis patients are either in complete response (CR) or already minimum residual disease (MRD)-negative.   To-date, all patients achieving MRD-negativity reached CR within one year of treatment.   Across all forty-five patients, NXC-201 produced an 89% (40/45) CR rate as assessed by independent review committee. In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98% (44/45). No relapses to date have been observed for any patient who reached CR or MRD-negativity to-date. No neurotoxicity or enterocolitis has been observed to-date.   NEXICART-2 final readout and BLA submission are planned in 2027.

“Today, patients with AL Amyloidosis face years of burdensome, continuous treatment. As a potential one-and-done treatment option, NXC-201 could liberate patients from that burden,” said Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma, adding: “We are thrilled with NXC-201’s magnitude of effect across a broad range of relapsed/refractory AL Amyloidosis patients in NEXICART-2.” Gabriel Morris, President of Immix Biopharma, added, “NXC-201’s complete response rate continues to increase over time, even as reported patient counts have now more than doubled.   We look forward to final readout, BLA submission and potentially making NXC-201 available to relapsed/refractory AL Amyloidosis patients at commercial launch.”

Investor Webcast and Conference Call Information
The Company will host a conference call to discuss these data at 8:00 a.m. ET today, Sep 29, 2026. The live webcast can be accessed at https://events.q4inc.com/attendee/484851283/ or under “Events & Presentations” in the Investors section of the company’s website at www.immixbio.com. The webcast will be available for replay on the company website. Analysts who wish to join the teleconference and participate in Q&A should register at the link above.

About NEXICART-2
NEXICART-2 (NCT06097832) is a multi-site U.S. Phase 2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. NEXICART-2 is a 45-patient study.

About AL Amyloidosis
AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death.

The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.

The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.

About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, statements relating to NEXICART-2 final readout and BLA submission planned in mid-2027; making NXC-201 available to patients at commercial launch, if approved; the size of the AL Amyloidosis market; the potential benefits of our product candidate NXC-201 and the timing and results related to clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the estimates for the number of patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size reaching not being accurate; (ii) the risk that Breakthrough Therapy designation will not expedite the development of NXC-201: (iii) the risk that further data from the ongoing Phase 1/2 clinical trials for NXC-201 will not be favorably consistent with the data readouts to date, (iv) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (v) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (vi) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (vii) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (viii) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (ix) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2026 and other periodic or current reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the filing of new intellectual property applying quantum sampling to disease biology and drug discovery. CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 million.

A copy of Sarborg’s full announcement is available below and at www.sarborg.com/news.

Sarborg Expands Quantum Computing Patent Portfolio, Applying Quantum Sampling to Disease Biology and Drug Targeting

WILMINGTON, De – September 29, 2026 – Sarborg Limited (“Sarborg” or the “Company“) today announced the filing of comprehensive novel intellectual property (IP) expanding its quantum computing applications into human drug discovery, utilising the expansive problem-solving efficiency of quantum sampling. Sarborg is also in active discussions with a leading global quantum computing company regarding a partnership to advance these dedicated models on market-leading quantum hardware.

Existing quantum computing work in drug discovery focuses on simulating individual molecules, but Sarborg’s novel application applies market-leading quantum computation to disease biology itself: the networks of regulators that switch disease genes on and off. Disease genes are frequently controlled by several regulators acting together, a combinatorial layer that conventional network methods cannot see and that grows rapidly harder to compute at scale. This approach requires the complexity of quantum sampling solutions.

The uniqueness of Sarborg’s intellectual property filing ensures a model that runs on existing classical infrastructure and produces commercially usable output, while being dedicated to maximising the current quantum processing capability and maintaining the full biological complexity of the model. To the Company’s knowledge, no other method combines quantum-ready sampling of disease network structure with a calibrated higher-order screen of this kind.

Applied across 150 disease networks in multiple indications, including Crohn’s disease, chronic obstructive pulmonary disease (COPD) and psoriasis, the model found that combinatorially regulated genes concentrate cell-surface receptors and ion channels, among the most targeted opportunities in pharmacology, and carry independent human genetic support for disease in all three conditions. In COPD, they aligned approximately eightfold with the disease’s own established drug targets, including CHRM3, the target of tiotropium. In a simulation against an exact ground truth, Sarborg’s quantum-enhanced sampler reproduced the model’s results with complete agreement, converging on a complex disease gene for which a matched classical sampler remained trapped.

This novel filing builds on the Company’s July 2026 quantum-enabled PRISM filing in agriculture and extends its patent estate across each layer of its Signature Intelligence models.

“Much of the quantum sector is still looking for problems that genuinely suit the hardware. We started from one,” said Dr. Andrew Regan, Chief Executive Officer of Sarborg. “Disease genes are controlled by committees of regulators acting together, a combinatorial layer conventional methods miss, and quantum samplers are built to explore. Our model delivers druggable, genetically supported targets today and is ready for quantum hardware by design. Our discussions with a leading quantum computing company to implement it in hardware are advancing strongly.”

About Sarborg Limited

Sarborg is an agentic AI and quantum computing signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures using its agentic AI and quantum computing infrastructure, Sarborg’s agents create a continuously evolving network of intelligence-driven insights.

Investors & Media:
info@sarborg.com
www.sarborg.com

About CDT Equity Inc.

CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT’s future results of operations and financial position, CDT’s business strategy, prospective product candidates, product approvals, research and development cost timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT’s control, you should not rely on these forward-looking statements as predictions of future events.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.

Investors
CDT Equity Inc.
Info@cdtequity.com  

• Plug and Arcadia eFuels enter a strategic cooperation agreement positioning Plug as the preferred electrolyzer supplier for more than 1 GW of Arcadia eFuels’ e-SAF projects in Europe and the Americas
• 280 MW of Plug’s GenEco electrolyzers will produce the hydrogen behind Project ENDOR at the Port of Vordingborg, Denmark
• Project ENDOR advances toward final investment decision

SLINGERLANDS, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced it has signed a 280-megawatt (MW) GenEco electrolyzer supply agreement with Arcadia eFuels for Project ENDOR in Denmark, together with a strategic cooperation agreement covering Arcadia’s future projects. The agreement follows three years of joint engineering work, and deliveries will begin after the project issues notice to proceed.

ENDOR is Arcadia eFuels’ flagship facility, located at the Port of Vordingborg on Denmark’s south coast. Once built, it will use renewable grid power to run 280 MW of Plug electrolyzers, producing roughly 110 tons of renewable hydrogen a day. Arcadia eFuels will combine that hydrogen with captured carbon dioxide to make jet fuel that works in standard aircraft.

The strategic cooperation agreement extends the relationship beyond ENDOR. It positions Plug as the preferred electrolyzer supplier for four additional Arcadia eFuels projects in Europe and the Americas, representing more than 1 GW of potential electrolyzer capacity, along with priority access for Arcadia eFuels to Plug’s manufacturing capacity as each project advances.

“Signing the ENDOR supply agreement alongside a strategic cooperation agreement positions Plug not only as the electrolyzer supplier for Arcadia eFuels’ flagship project, but as their preferred partner across a pipeline of e-SAF developments in Europe and the Americas,” said José Luis Crespo, President and Chief Executive Officer of Plug. “This reflects continued confidence in our GenEco technology, our manufacturing capacity, and Plug’s ability to deliver complex, high-capacity projects at scale. Europe remains our most active electrolyzer market, and e-SAF is one of the fastest-growing segments of demand as aviation fuel mandates take effect. Producing that fuel from European electricity and European carbon rather than imported oil also strengthens the continent’s energy security.”

“Project ENDOR is on the path to final investment decision, and this supply agreement from Plug signifies one of the many project documents that have been finalized,” said Amy Hebert, Chief Executive Officer of Arcadia eFuels. “Sustainable aviation fuel made from renewable hydrogen and captured carbon is what will get aviation to its decarbonization targets, and Plug gives us a proven and bankable electrolyzer partner at the scale this project demands.”

e-SAF is produced from renewable electricity and captured carbon rather than crude oil. The EU’s ReFuelEU Aviation mandate requires a rising share of sustainable aviation fuel at European airports, including a sub-target reserved for synthetic fuels from 2030, which makes projects like ENDOR both a compliance route for airlines and a domestic source of aviation fuel for Europe.

Plug is executing multiple projects with a combined capacity in the multi-gigawatt range across Denmark, the U.K., Spain and Portugal, including the 100 MW GenEco installation at Galp’s Sines refinery. Project ENDOR extends that footprint into e-fuels as aviation fuel mandates take effect.

About Plug Power
Plug is building the global hydrogen economy with a fully integrated ecosystem spanning production, storage, delivery, and power generation. A first mover in the industry, Plug provides electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure to customers worldwide across material handling, industrial applications, and energy production, advancing energy independence and decarbonization at scale.

Plug has deployed electrolyzers on five continents, along with more than 76,000 fuel cell systems and 275 fueling stations, and is the world’s largest user of liquid hydrogen. Its expanding generation network produces 40 tons of hydrogen per day, supplying large-scale projects that redefine industrial power for customers globally.

Headquartered in New York, with employees and state-of-the-art manufacturing facilities around the world, Plug powers global leaders like BMW, BP, Walmart, Amazon, and Home Depot.

For more information, visit www.plugpower.com.

About Arcadia eFuels
Arcadia eFuels is committed to building facilities to produce the world’s future fuels. These net-zero carbon fuels will allow the transport sector, namely aviation and shipping, to use fuels directly, without changes to existing engines and infrastructure. Arcadia eFuels aims to produce fuels worldwide to help meet the aviation industry’s decarbonization goals.

Please visit www.arcadiaefuels.com to learn more or contact us at info@arcadiaefuels.com.

Plug Safe Harbor

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts, including, without limitation, statements regarding the expected development, financing, construction, final investment decision (“FID”), operation, timing, capacity, and performance of Project ENDOR; the anticipated supply and deployment of Plug’s GenEco™ electrolyzers; expected renewable hydrogen production volumes; the production, market demand for, and adoption of e-sustainable aviation fuel (“e-SAF”) and other synthetic fuels; the benefits of the strategic cooperation agreement with Arcadia eFuels; Plug’s status as Arcadia eFuels’ preferred electrolyzer supplier; potential future orders, projects, and opportunities associated with Arcadia eFuels’ development pipeline; anticipated regulatory support, mandates, and market conditions for hydrogen and e-fuels; Plug’s growth opportunities in Europe, the Americas, and other markets; and other statements regarding the Company’s future operating results, financial condition, business strategy, performance, prospects, objectives, plans, and opportunities, are forward-looking statements. In addition, certain statements in this press release relating to Arcadia eFuels, Project ENDOR, and Arcadia eFuels’ other projects are based in part on information provided by Arcadia eFuels, or other third parties, which the Company has not independently verified, and the Company assumes no responsibility for the accuracy or completeness of such third-party information. Forward-looking statements can generally, but not always, be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “continue,” “project,” “potential,” “target,” “outlook,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among other things: whether Project ENDOR achieves FID and proceeds to construction and operation; whether Arcadia eFuels’ additional projects in Europe and the Americas advance as currently anticipated; whether any potential future electrolyzer orders or projects materialize under the strategic cooperation agreement; the ability of the parties to satisfy contractual, financing, permitting, regulatory, and technical milestones; the availability and cost of renewable electricity and captured carbon dioxide; whether projected hydrogen production volumes, plant performance metrics, and e-SAF production targets are achieved; the development, economics, competitiveness, and demand for hydrogen, e-SAF, and synthetic fuels; changes in applicable laws, regulations, government incentives, sustainability mandates, and aviation fuel requirements; supply chain constraints, inflationary pressures, and project execution risks; Plug’s ability to manufacture, deliver, install, and service its electrolyzer systems on anticipated schedules; the Company’s ability to manage costs, maintain liquidity, and secure additional financing as needed; and general economic, market, competitive, geopolitical, and regulatory conditions. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Plug’s business generally, see Plug’s public filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of Plug’s Annual Report on Form 10-K for the year ended December 31, 2025, Plug’s subsequent Quarterly Reports on Form 10-Q and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which are not guarantees of future performance and speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

PLUG MEDIA CONTACT
Teal Hoyos
media@plugpower.com

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Barrick Mining Corporation (NYSE:B)(TSX:ABX) will present today at Mining Forum Americas 2026. Barrick’s leaders will review progress, plans, and growth opportunities across the world-class portfolios of its two operating regions, North America and Rest of World.

Presenting for Barrick will be:

• Mark Hill, President and Chief Executive Officer
• Tim Cribb, Chief Operating Officer, North America
• Sebastiaan Bock, Chief Executive Officer, Rest of World

Mark Hill and Tim Cribb will outline the North American portfolio’s potential for sustained production and growth, including opportunities to expand production through brownfield development, infrastructure investments, and exploration. Some of these initiatives have the potential to raise annual gold production at NGM to more than three million ounces for the next decade.

Seb Bock will provide an update on Barrick’s Rest of World business, including the ramp-up of Loulo-Gounkoto, construction progress at the Lumwana Super Pit Expansion, and a pipeline of exciting future growth opportunities competing for capital in a disciplined allocation framework.

“Our job is straightforward: operate safely, deliver our guidance, and deliver our growth projects,” said Hill.

Barrick’s presentation begins today at 9:00 a.m. Mountain Time. A live webcast will be available at https://mf.live/?play4440, and the presentation deck is available to download now at www.barrick.com.

About Barrick Mining Corporation

Barrick is a leading global mining, exploration, and development company. With one of the largest portfolios of world-class and long-life gold and copper assets in the industry, Barrick’s operations and projects span 17 countries and five continents. Barrick is also the largest gold producer in the United States. We create real, long-term value for all stakeholders through responsible mining, strong partnerships, and a disciplined approach to growth. Barrick shares trade on the New York Stock Exchange under the symbol ‘B’ and on the Toronto Stock Exchange under the symbol ‘ABX’.

Investor Relations Contact: investor@barrick.com
Media Contact: media@barrick.com

Cautionary Statement on Forward-Looking Information

Certain information contained or incorporated by reference in this press release, including any information as to our strategy, projects, plans or future financial or operating performance, constitutes “forward-looking statements”. All statements, other than statements of historical fact, are forward-looking statements. The words “ramp up”, “future”, “growth”, “opportunity”, “outline”, “expand”, “progress”, “continue”, “focus”, “will”, “could”, and similar expressions identify forward-looking statements. In particular, this press release contains forward-looking statements including, without limitation, with respect to: anticipated production growth from Barrick’s organic project pipeline, including through brownfield development, infrastructure investments and exploration success; potential future production at Nevada Gold Mines and Pueblo Viejo, including initiatives that could support Nevada Gold Mines as a more than three-million-ounce annual gold complex for more than a decade; the prospects of our Rest of World business, including our plans and expected completion and benefits of our growth projects, including the Lumwana Super Pit Expansion, our pipeline of future growth opportunities at or near existing operations and the ramp-up of operations at Loulo-Gounkoto; Barrick’s planned exploration activities; joint ventures and partnerships; Barrick’s intention to continue to improve safety performance; and Barrick’s disciplined capital allocation framework.

Forward-looking statements are necessarily based upon a number of estimates and assumptions including material estimates and assumptions related to the factors set forth below that, while considered reasonable by the Company as at the date of this press release in light of management’s experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information. Such factors include, but are not limited to: fluctuations in the spot and forward price of gold, copper or certain other commodities (such as silver, diesel fuel, natural gas and electricity); risks associated with projects in the early stages of evaluation and for which additional engineering and other analysis is required; risks related to the possibility that future exploration results will not be consistent with the Company’s expectations, that quantities or grades of reserves will be diminished, and that resources may not be converted to reserves; risks associated with the fact that certain of the initiatives described in this press release are still in the early stages and may not materialize; changes in mineral production performance, exploitation and exploration successes; risks that exploration data may be incomplete and considerable additional work may be required to complete further evaluation, including but not limited to drilling, engineering and socioeconomic studies and investment; the speculative nature of mineral exploration and development; lack of certainty with respect to foreign legal systems, corruption and other factors that are inconsistent with the rule of law; disruption of supply routes which may cause delays in construction and mining activities, including disruptions in the supply of key mining inputs due to the invasion of Ukraine by Russia and conflicts in the Middle East; risk of loss due to acts of war, terrorism, sabotage and civil disturbances; risks associated with artisanal and illegal mining; changes in national and local government legislation, taxation, controls or regulations and/or changes in the administration of laws, policies and practices; expropriation or nationalization of property and political or economic developments in Canada, the United States or other countries in which Barrick does or may carry on business in the future; risks relating to political instability in certain of the jurisdictions in which Barrick operates; timing of receipt of, or failure to comply with, necessary permits and approvals; non-renewal of key licenses by, or failure to obtain key licenses from governmental authorities; failure to comply with environmental and health and safety laws and regulations; increased costs and physical and transition risks related to climate change, including extreme weather events, resource shortages, emerging policies and increased regulations relating to greenhouse gas (“GHG”) emission levels, energy efficiency and reporting of risks; Barrick’s ability to achieve its sustainability goals, including its climate related goals and GHG emissions reduction targets; contests over title to properties, particularly title to undeveloped properties, or over access to water, power and other required infrastructure; the liability associated with risks and hazards in the mining industry, and the ability to maintain insurance to cover such losses; damage to the Company’s reputation due to the actual or perceived occurrence of any number of events, including negative publicity with respect to the Company’s handling of environmental matters or dealings with community groups, whether true or not; risks related to operations near communities that may regard Barrick’s operations as being detrimental to them; litigation and legal and administrative proceedings; operating or technical difficulties in connection with mining or development activities, including geotechnical challenges, tailings dam and storage facilities failures, and disruptions in the maintenance or provision of required infrastructure and information technology systems; increased costs, delays, suspensions and technical challenges associated with the construction of capital projects; risks associated with working with partners in jointly controlled assets; risks associated with Barrick’s infrastructure, information technology systems and the implementation of Barrick’s technological initiatives, including risks related to cybersecurity incidents, including those caused by computer viruses, malware, ransomware and other cyberattacks, or similar information technology system failures, delays and/or disruptions; the impact of global liquidity and credit availability on the timing of cash flows and the values of assets and liabilities based on projected future cash flows; the impact of inflation, including global inflationary pressures driven by ongoing global supply chain disruptions, global energy cost increases following the invasion of Ukraine by Russia and country-specific political and economic factors in Argentina and uncertainty related to Venezuela; adverse changes in our credit ratings; fluctuations in the currency markets; changes in U.S. dollar interest rates; changes in U.S. trade, tariff and other controls on imports and exports, tax, immigration or other policies that may impact relations with foreign countries, result in retaliatory policies, lead to increased costs for raw materials and components, or impact Barrick’s existing operations and material growth projects; risks arising from holding derivative instruments (such as credit risk, market liquidity risk and mark-to-market risk); risks related to the demands placed on the Company’s management, the ability of management to implement its business strategy and enhanced political risk in certain jurisdictions; uncertainty whether some or all of Barrick’s targeted investments and projects will meet the Company’s capital allocation objectives and internal hurdle rate; whether benefits expected from recent transactions are realized; business opportunities that may be presented to, or pursued by, the Company; our ability to successfully integrate acquisitions or complete divestitures; risks related to competition in the mining industry; employee relations including loss of key employees; availability of and increased costs associated with mining inputs and labor; risks associated with diseases, epidemics and pandemics; risks related to the failure of internal controls; and risks related to the impairment of the Company’s goodwill and assets. In addition, there are risks and hazards associated with the business of mineral exploration, development and mining, including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins, flooding and gold bullion, copper cathode or gold or copper concentrate losses (and the risk of inadequate insurance, or inability to obtain insurance, to cover these risks).

Many of these uncertainties and contingencies can affect our actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, us. Readers are cautioned that forward-looking statements are not guarantees of future performance. All of the forward-looking statements made in this press release are qualified by these cautionary statements. Specific reference is made to the most recent Form 40-F/Annual Information Form on file with the SEC and Canadian provincial securities regulatory authorities for a more detailed discussion of some of the factors underlying forward-looking statements and the risks that may affect Barrick’s ability to achieve the expectations set forth in the forward-looking statements contained in this press release.

Barrick disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

• NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research
• CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain
• Nociscan^® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI)

BROOMFIELD, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced NYU Langone Health as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial. The groundbreaking CLARITY study is designed to demonstrate Nociscan’s clinical and economic value in spine surgery.

The NYU Langone Spine Center is one of the nation’s most comprehensive spine care programs, offering both nonsurgical and surgical treatment of degenerative spine conditions. Ranked No. 1 in the nation for neurology and neurosurgery and No. 2 for Orthopedic Surgery by U.S. News & World Report, the Spine Center serves more than 25,000 patients each year, with its surgical team performing more than 4,700 procedures annually. The program takes a collaborative approach to care, bringing together orthopedic surgeons, neurosurgeons, physiatrists, and rehabilitation specialists under one roof.

“Every patient who comes to me with chronic low back pain has a story — potentially years of trying to find answers, manage symptoms, and get their life back. As surgeons, we owe it to them to use appropriate tools to understand what is truly driving their pain before we recommend treatment,” said Jeffrey A. Goldstein, MD, Director, Spine Surgery Fellowship Program and Clinical Professor of Orthopedic Surgery and Neurosurgery, NYU Grossman School of Medicine, NYU Langone Health.

NYU Langone Health joins a growing network of high-volume CLARITY trial sites including Johns Hopkins University, Northwestern Medicine, Advocate Aurora Research Institute, Texas Back Institute, Keck Medicine at USC, UHealth — University of Miami Health System, Scripps Health, Lanman Spinal Neurosurgery, Texas Spine Care Center, and University of Arizona College of Medicine – Phoenix. The principal investigator for the trial is Dr. Nicholas Theodore, Chairman of Neurosurgery at the University of Arizona College of Medicine – Phoenix at Banner – University Medical Center Phoenix.

The CLARITY trial is a 300-patient, prospective, randomized, multi-center study evaluating Nociscan in patients undergoing surgical treatment (Fusion / TDR) for discogenic low back pain. The primary endpoint is change in back pain as measured on a 100mm VAS Back at 12 months compared to baseline, with several secondary endpoints collected.

“NYU Langone Health is one of the most respected academic medical centers in the country, and Dr. Goldstein is widely recognized for his expertise in spine surgery and his commitment to innovation and research,” said Ryan Bond, Chief Strategy Officer of Aclarion. “Their addition to the CLARITY network reflects the growing interest among leading institutions in the clinical value Nociscan can bring to surgical decision-making for chronic low back pain.”

Chronic low back pain is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.

For more information about CLARITY, please visit: CLARITY Trial

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: info@aclarion.com

All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein.

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition.  Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the growing interest in integrating Nociscan into real-world clinical workflows and, the continued expansion of the CLARITY trial to generate the high-quality evidence needed to advance Nociscan. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

Media Contacts:

Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com

• Trilivy™ is designed to address the challenges of metabolic dysfunction
• Clients on Trilivy’s Reset 5 & 1 Plan who work with a coach lose up to 10 times more weight and 17 times more fat compared to self-directed approaches*

Baltimore, MD, Sept. 29, 2026 (GLOBE NEWSWIRE) — A weight loss plateau is one of the most common reasons people abandon a structured weight loss effort altogether. The body stops losing weight when metabolic dysfunction interferes with the fat-burning process, and without a framework built to identify what’s happening beneath the surface, a stall can look like failure rather than a solvable metabolic pattern. Trilivy™, a science-backed, coach-guided comprehensive metabolic health system, points to five metabolic and behavioral factors behind why plateaus happen and why they tend to compound with each subsequent attempt. 

“Body composition research points to a consistent pattern: when lean mass isn’t protected during weight loss, resting metabolic rate can be affected. Repeated cycles of weight loss may compound those changes, which is why body composition should be addressed from the first week,” said Satya Jonnalagadda, PhD, MBA, RD, Vice President, Scientific & Clinical Affairs at Trilivy, who leads the company’s scientific and clinical research strategy.

A Weight Loss Plateau Reflects a Metabolic Problem

Five reasons weight loss plateaus occur are highlighted below. 

1. Lean Mass Is Lost Alongside Fat, Lowering the Metabolic Rate

When weight loss happens without a structured nutrition (protein) and lifestyle framework, the body breaks down lean tissue as well as fat to meet its energy needs. Lean mass, around 50% of which is muscle, makes up the body’s non-fat composition and it is metabolically active. As it declines, so does resting metabolic rate, which is the number of calories the body burns at rest. Protecting lean mass prevents the metabolic rate suppression that makes later progress more challenging.

2. Visceral Fat Disrupts the Metabolic Environment

Visceral fat is a metabolically active tissue that releases inflammatory molecules and hormones affecting insulin sensitivity and energy regulation. As visceral fat accumulates, it changes the way the metabolism works, making the body progressively more insulin resistant and less efficient at burning fat for fuel. This determines whether the metabolic environment supports continued fat loss.

3. A Weight Loss Plateau in the First Four Weeks Predicts the Long-term Outcome

How a person responds in the first four weeks of a weight loss program is a strong predictor of the final outcome. A secondary data analysis found that what happens in the first four weeks of a weight loss program predicts the final outcome, and individuals who stall early need additional support rather than an entirely new protocol.¹ A plateau acts as a signal, and the presence of a coach can help catch this signal early on to redirect it.

4. No Accountability Layer Means No Behavioral Correction at the Plateau

Without a structured accountability layer, there is no mechanism to catch a stall early or correct course before it takes hold. The presence of one-on-one support gives an individual a way to identify the pattern behind a plateau and stay engaged through the period when adherence typically breaks down, rather than abandoning the effort altogether.

5. Body Composition Is the Signal That Matters During a Metabolic Reset

Body composition, specifically a reduction in visceral fat levels and lean mass retention, reflects what is biologically changing in the metabolic environment. Individuals may not see external progress even while visceral fat is actively being reduced, and without body composition data, that stall can read as failure. 

How Trilivy’s Metabolic Synchronization® Addresses Weight Loss Plateaus

Trilivy is built around Metabolic Synchronization®, a breakthrough science that reverses metabolic dysfunction through targeted metabolic reset. 

Key Facts:

• 14% reduction in visceral fat and 98% of lean mass retained at 16 weeks among individuals on the Trilivy Reset 5 & 1 Plan*
• Coach-supported participants lost up to 10 times more weight and 17 times more fat than those following the same plan without a coach*

The metabolic variables that drive a plateau, including visceral fat accumulation, lean mass loss, and suppressed resting metabolic rate, respond to structured intervention. A plan that measures and protects those variables creates the conditions for progress beyond the stall.

FAQs

Question: What does a metabolic reset involve in a weight loss program?

Answer: A metabolic reset targets the body composition variables that drive weight loss stalls, specifically visceral fat reduction and lean mass preservation. Programs built around this framework adjust resting metabolic rate by protecting lean tissue during the fat loss phase, rather than allowing muscle depletion to suppress metabolism further.

Question: What makes a weight loss program effective for someone who has already hit a plateau?

Answer: Plateau-specific effectiveness requires addressing the metabolic conditions that caused the stall. Tracking visceral fat and lean mass retention alongside body weight can identify whether metabolic progress is continuing even when external changes are difficult to see. But lasting progress also depends on the habits that support metabolic health: consistent nutrition, movement, sleep, and other healthy routines. Community and human connection can help reinforce those habits. Together, these factors can help inform the next intervention step.

Question: What does a weight loss program need to include to help someone keep weight off long-term?

Answer: Long-term weight management requires protecting lean mass during the weight loss phase, since lean tissue supports resting metabolic rate after the deficit ends. Look for programs that pair structured nutrition with one-on-one behavioral accountability since the behavioral layer addresses the adherence patterns that determine whether results last beyond the active program. A combination of nutrition, lifestyle and behavior modifications, and exercise can contribute to weight management. 

Trilivy™ recommends that you contact your healthcare provider before starting and throughout your weight loss journey.

* Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obesity Science & Practice. 2019. https://onlinelibrary.wiley.com/doi/10.1002/osp4.312. In a clinical study, individuals on the Reset 5 & 1 Plan experienced a reduction of 14% visceral fat and 98% of lean mass was retained at 16 weeks. Those on the Reset 5 & 1 Plan with the support of a coach lost up to 10x more weight and 17x more fat than those who tried to lose weight on their own.

¹ Coleman CD, Guarneiri LL, Kiel JR, et al. Importance of early weight loss and other predictors of lower weight loss in a commercial program: a secondary data analysis. Obesity Science and Practice. 2024;10(1):e724. doi: 10.1002/osp4.724.

About Medifast and Trilivy
Medifast (NYSE: MED) is the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy. Designed to address the challenges of metabolic dysfunction, the company’s holistic approach integrates science-backed plans and products, personal 1:1 coaching, a supportive community, and behavioral science support to develop healthy habits.
Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization®, a breakthrough science that targets metabolic dysfunction through a comprehensive system focused on fat loss, lean mass preservation, and long-term health. Trilivy’s comprehensive three-phase metabolic health system is designed to help people reset their metabolism, refine their health, and renew their lives. By integrating science, coaching, and healthy habits into a single approach, Trilivy helps people look, feel, and live better.
Backed by more than 45 years of clinical heritage, Medifast continues to advance its mission of lifelong transformation through metabolic science and human connection™. For more information, visit trilivyhealth.com and medifastinc.com.

CONTACT: Sarah Evans, CEO
Zen Media
sarah@zenmedia.com

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, today announced that its enterprise-grade AI agent platform, GPTBots.ai, is helping Ruko embed AI-powered customer assistance across its app, website, and ticket workflows. Powered by GPTBots.ai, Ruko has cut ticket response time from approximately two hours to under 10 minutes.

Image source: Ruko official website

Expanding Channels, Growing Service Demands
Ruko is a consumer electronics brand ranked among the top 15 drone brands globally in 2026, with products sold through Amazon, Best Buy, Walmart, and TikTok. The brand’s smart robot product line has been top-ranked in US toy robot buying guides, with strong buyer ratings on BestBuy.com.

As Ruko expanded across these channels, its customer feedback volume more than doubled. Rather than overhaul its existing support infrastructure, Ruko chose GPTBots.ai’s enterprise-grade platform to bring AI-powered assistance and product knowledge directly into the workflows its team already used.

Ruko chose GPTBots.ai with one primary goal in mind: to deliver a better service experience for customers, respond quickly to their inquiries, and consistently meet the expectations and hopes they place in us—just as Ruko’s service philosophy says: “A great drone company is, first and foremost, a great service company.”  

Bringing Product Knowledge into Daily Support
Through GPTBots.ai, Ruko has built a three-layer AI support system that works inside its existing Zendesk workflows—from frontline responses to backend knowledge ownership:

• Online AI assistance: Powered by GPTBots.ai, Ruko’s AI assistants on app and website have handled over 3,000+ customer inquiries in 6 months, deflecting repetitive questions and freeing the team to focus on complex issues.
• Zendesk ticket acceleration: GPTBots.ai powers AI-assisted replies directly inside Ruko’s Zendesk ticket queue. According to Ruko, this integration has cut ticket response time from approximately two hours to under 10 minutes—a 12x improvement.
• Knowledge ownership: Unlike single-purpose service agents, GPTBots.ai lets Ruko’s team directly manage and refine the product knowledge behind every AI response—so as product lines evolve or customer issues change, the AI stays accurate without waiting for model retraining. This is the platform advantage: Ruko owns the knowledge, GPTBots.ai provides the execution layer.

Building Service Capacity Alongside Sales Growth
GPTBots.ai enables Ruko to scale AI-powered customer support without replacing existing systems. The platform delivers faster response times, product-accurate answers, and—critically—gives Ruko direct control over the knowledge and quality behind every AI interaction. This is the difference between a one-time AI deployment and a sustainable, business-owned capability.

“As Ruko’s product sales grow and its sales channels expand, customer inquiries continue to rise,” said Hailey, Customer Service Manager of Ruko. “We needed AI that could scale with us—but we also needed to stay in control of how our products were represented. GPTBots.ai gave us both. Our ticket response time dropped from hours to minutes, and we never had to give up ownership of our product knowledge or how the AI speaks on our behalf.”

“Customer support shouldn’t be the bottleneck of sales growth,” said Chris Lo, Founder and CEO of GPTBots.ai. “Brands like Ruko are proving that you can cut response times by 12x without giving up control of how your AI answers. That’s what an enterprise-grade AI agent platform is for—fast enough to keep pace with growth, accurate enough to keep improving, and always under the business’s control.”

Looking ahead, GPTBots.ai will continue helping enterprises build, own, and evolve their AI-powered customer support—turning every product launch, every channel expansion, and every customer question into an opportunity to deliver faster, smarter, and more controlled service.

About Ruko
Ruko is a consumer electronics brand ranked among the top 15 drone brands globally in 2026, with products sold through Amazon, Best Buy, Walmart, and TikTok. The brand’s smart robot product line has been top-ranked in US toy robot buying guides, with strong buyer ratings on BestBuy.com.

About GPTBots.ai
GPTBots.ai is an enterprise-grade AI agent platform under Aurora Mobile (NASDAQ: JG), offering no-code/low-code AI agent development, deployment, and management for enterprise clients. Through multi-model LLM integration and intelligent workflow automation, GPTBots.ai empowers organizations to enhance customer service, optimize knowledge management, and automate business processes, driving digital innovation and transformation worldwide.

GPTBots.ai’s global customers include Axios Management, GP Batteries, and many more.

For more information, please contact: marketing@gptbots.ai

About Aurora Mobile Limited
Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services. The Company is dedicated to empowering global enterprises with stable, efficient, and intelligent customer interaction solutions. Leveraging its first-mover advantage in mobile messaging, Aurora Mobile has evolved into a comprehensive platform that integrates Omnichannel Engagement, AI-Driven Marketing, Advanced AI Customer Support, and Frictionless Identity Security. Through its flagship brand EngageLab and its robust AI infrastructure GPTBots.ai, the Company helps businesses achieve seamless customer reach, automate complex marketing journeys, and optimize service efficiency with AI agents, accelerating digital transformation for clients worldwide.

For more information, please visit: https://ir.aurora-mobile.com/
Media contact: marketing@aurora-mobile.com

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability to maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law. 

For more information, please contact:
Aurora Mobile Limited
E-mail: ir@aurora-mobile.com

Christensen Advisory
Ms. Xiaoyan Su
E-mail: Xiaoyan.Su@christensencomms.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a704ef74-8f52-4957-b2de-b2ffd34b9987

Strategic partnership delivers operational continuity today and a multi-year plan to strengthen Columbia Sportswear’s European supply chain

PARIS, France, Sept. 29, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced the launch of a new 10-year strategic relationship with Columbia Sportswear Company, a global leader in outdoor, active and lifestyle products. GXO is now managing Columbia’s European distribution center in Cambrai, France.

“We are proud to serve Columbia Sportswear in Europe,” said Vincent Ricci, Managing Director, GXO France. “Our team has delivered a seamless transition of this critical distribution operation, and together we have established a multi-year roadmap that is designed to enhance agility and strengthen Columbia Sportswear’s supply chain across the region.”

Matthieu Schegg, SVP & GM for EMEA, Columbia Sportswear, said: “At Columbia Sportswear, we partner with world‑class experts like GXO, as we advance our distribution and logistics transformation, leveraging their capabilities to strengthen our supply chain in Europe and deliver consistent multi‑channel service for our customers.”

Supporting Columbia’s European operations
The distribution center operated by GXO is located in Cambrai, Northern France, and is Columbia Sportswear’s primary distribution hub for continental Europe, supporting e-commerce fulfillment, retail replenishment and wholesale distribution. From this strategic location, GXO will manage inbound logistics, storage, order fulfillment and outbound distribution activities serving multiple European markets.

The transition was prepared jointly by Columbia Sportswear and GXO with a focus on operational continuity, employee integration and maintaining uninterrupted service for customers.

GXO in France
GXO has been helping customers in France optimize their logistics for several decades and operates over 60 warehouses throughout the country. Currently ranked the #2 logistics service provider in France by Supply Chain Magazine, GXO manages logistics for customers in a variety of sectors, including ecommerce, retail, FMCG and technology. In France, GXO employs nearly 8,500 team members.

About Columbia Sportswear Company
Columbia Sportswear Company connects active people with their passions and is a global multi-brand leading innovator in outdoor, active and lifestyle products including apparel, footwear, accessories, and equipment. Founded in 1938 in Portland, Oregon, the Company’s brands are sold in 122 countries. In addition to the Columbia® brand, Columbia Sportswear Company also owns the Mountain Hard Wear®, SOREL® and prAna® brands. To learn more, please visit the Company’s websites at www.columbia.com, www.mountainhardwear.com, www.sorel.com, and www.prana.com.

About GXO Logistics
GXO Logistics, Inc. (NYSE: GXO) is the world’s largest pure-play contract logistics provider and is positioned to capitalize on the rapid growth of ecommerce, automation and outsourcing. GXO has more than 150,000 team members across more than 1,000 facilities totaling more than 200 million square feet. The company serves the world’s leading blue-chip companies to solve complex logistics challenges with technologically advanced supply chain and ecommerce solutions, at scale and with speed. GXO corporate headquarters is in Greenwich, Connecticut. Visit GXO.com for more information and connect with GXO on LinkedIn, X, Facebook, Instagram and YouTube.

Media contacts
Claudia Roux 
+33 (0)6 28 45 59 72
claudia.roux@gxo.com 

Matthew Schmidt 
+1 203-307-2809 
matt.schmidt@gxo.com